| Oct 21 |
Adagene And 2 Other US Penny Stocks To Consider
|
| Oct 9 |
Adagene Announces Upcoming Poster Presentations on Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) at Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting
|
| Sep 27 |
Is DaVita (DVA) Stock Outpacing Its Medical Peers This Year?
|
| Sep 16 |
Why Exicure Shares Are Trading Higher By Over 49%; Here Are 20 Stocks Moving Premarket
|
| Sep 16 |
Adagene Presents Results at ESMO Congress that Show Best-in-Class Therapeutic Potential for Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) in Combination with KEYTRUDA® (Pembrolizumab) in Advanced/Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC)
|
| Sep 11 |
Are Medical Stocks Lagging Adagene (ADAG) This Year?
|
| Aug 29 |
Adagene to Participate in Investor Conferences in September
|
| Aug 26 |
Is Adagene (ADAG) Stock Outpacing Its Medical Peers This Year?
|
| Aug 9 |
Is MannKind (MNKD) Stock Outpacing Its Medical Peers This Year?
|
| Jul 28 |
Adagene First Half 2024 Earnings: US$0.39 loss per share (vs US$0.094 loss in 1H 2023)
|
